Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

  • Price (GBX)694.00
  • Today's Change-6.00 / -0.86%
  • Shares traded56.39k
  • 1 Year change10.16%
  • Beta0.1840
Data delayed at least 20 minutes, as of Sep 20 2024 16:19 BST.
More ▼
Total returns on £1000
1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)+17.13%
NAVInternational Biotechnology Trust (Ordinary Share)+19.50%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Key statistics

On Friday, International Biotechnology Trust (IBT:LSE) closed at 694.00, -3.61% below its 52-week high of 720.00, set on Jul 26, 2024.
52-week range
Today
548.00Oct 27 2023720.00Jul 26 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding36.71m
Market cap257.00m GBP
Total assets303.06m GBP
Total expense ratio1.44%
High694.00
Low688.00
Previous close700.00
Average volume42.89k
YTD Change+8.10%
Beta0.1840
Diluted NAV (est)751.09
Diluted NAV (last pub)753.40
Premium/Discount-8.07%
Net Gearing+5.46%
Annual div (ADY)28.40 GBX
Annual div yield (ADY)4.09%
Div ex-dateJul 25 2024
Div pay-dateAug 23 2024
Data delayed at least 20 minutes, as of Sep 20 2024 16:19 BST.
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.